Selected Publications
Sannigrahi MK, Raghav L, Rich DJ, Schrank TP, Califano JA, Lukens JN, Sun L, Morgan IM, Cohen RB, Lin A, Liu X, Brown EJ, You J, Mirabello L, Mishra SK, Shimunov D, Brody RM, Pearson AT, Gimotty PA, Diab A, Jalaly JB, Basu D.: Tumor-intrinsic and immune-related features associated with treatment failure in human papillomavirus-related oropharyngeal cancer J Natl Cancer Inst : 2025.
Riaz F, Vaughn JL, Zhu H, Dickerson JC, Sayegh HE, Brongiel S, Baldwin E, Kier MW, Zaemes J, Hearn C, Abdelghany O, Cohen RB, Parikh RB, Reuss JE, Prsic E, Doroshow DB.: Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis JCO Oncol Pract : 2025.
Stalker M, Qu K, Cohen RB, Mamtani R, Hwang WT, Sun L.: "Off-Label" Use of Checkpoint Inhibitors in Patients With Negative or Unknown PD-L1 Status in Advanced Head and Neck Cancer J Natl Compr Canc Netw 23 : 90-96,2025.
Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA.: Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies Nat Med : 2025.
Elghawy O, Barsouk A, Reed-Guy L, Stalker M, Sussman J, Robinson K, Kosteva J, Singh A, Cohen RB, Langer C, Ciunci C, D'Avella C, Sun L, Marmarelis ME, Aggarwal C.: Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy Clin Lung Cancer : 2024.
Elghawy O, Barsouk A, Xu J, Chen S, Cohen RB, Sun L.: Real word outcomes of cabozantinib therapy in poorly differentiated thyroid carcinoma Eur Thyroid J 13 : e240225,2024.
Sannigrahi MK, Raghav L, Rich DJ, Schrank TP, Califano JA, Lukens JN, Sun L, Morgan IM, Cohen RB, Lin A, Liu X, Brown EJ, You J, Mirabello L, Mishra SK, Shimunov D, Brody RM, Pearson AT, Gimotty PA, Diab A, Jalaly JB, Basu D.: Association of oropharyngeal cancer recurrence with tumor-intrinsic and immune-mediated sequelae of reduced genomic instability bioRxiv : 2024.
Stalker M, Marmarelis M, Langer C, Cohen RB, Singh A, Aggarwal C, Sun L.: Outcomes Following Treatment for Progression in Patients Treated With Durvalumab Consolidation in LA-NSCLC Clin Lung Cancer : 2024.
Elghawy O, Barsouk A, Heidlauf A, Chen S, Cohen RB, Sun L.: Single-Institution Experience of Larotrectinib Therapy for Patients With NTRK Fusion-Positive Thyroid Carcinoma J Endocr Soc 8 : bvae158,2024.
Sun L, Cohen RB, Dimitrios Colevas A.: Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC) Oral Oncol 158 : 106997,2024.
Academic Contact Information
Division of Hematology-Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-139
Philadelphia,
PA
19104
Phone: 215-662-4469
Patient appointments: 800-789-7366